For a few weeks in January, Valeant Pharmaceuticals '(NYSE: VRX) stock outperformed the S&P 500 index. The run didn't last long, though. Here's why Valeant's rebound quickly fizzled. The first phase ...

Valeant Pharmaceuticals International won big with ribavirin, its hepatitis C treatment, in the past. Now with generic versions of the drug eating into a big chunk of its ribavirin sales, the Costa ...

Valeant Phramaceuticals is defending its drug discount program for two expensive heart drugs against reports that hospitals are not seeing any savings. The Canadian drugmaker said the program will ...

Berna Heyman told a Senate committee Wednesday that her annual co-payment for a lifesaving drug needed to treat an ailment known as Wilson disease stayed below $700, a manageable cost, until 2013.

Costa Mesa-based Valeant Pharmaceuticals International said Tuesday that it’s completed two safety studies for a key drug in its pipeline. The drug candidate,Zelapar,is a pill that could be used in ...

T. Rowe Price Group, one of the largest investment managers in the world, is suing Valeant Pharmaceuticals over billions of dollars it lost due to the Canadian drugmaker’s alleged ‘fraudulent scheme,’ ...

The lawsuit claims the company targeted minority women and children despite being aware of the risk of asbestos in talc. By Tiffany Hsu The world’s most prestigious consulting firm has a secretive $12 ...

Valeant Pharmaceuticals this month agreed to delay the launch of efinaconazole, a drug for treating a nail fungal condition, until after an arbitration hearing in ...

's stock got a boost on Wednesday after the U.S. Food and Drug Administration (FDA) approved the company's RELISTOR Tablets for the treatment of opioid-induced constipation in adults with chronic ...